EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease

Mary M McDermott, Kathryn J Domanchuk, Lu Tian, Lihui Zhao, Dongxue Zhang, Lydia Bazzano, Scott Berceli, Michael H Criqui, Luigi Ferrucci, Jack M Guralnik, Christiaan Leeuwenburgh, Karen J Ho und 10 weitere

JAMA · 03.02.2026 · 335 (5) · 407

DOI: 10.1001/jama.2025.21358 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 03.02.2026. Verfasst von Mary M McDermott und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Lower Extremity, Metformin, Peripheral Arterial Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Lower extremity peripheral artery disease (PAD) is a disabling cardiovascular condition that impairs walking ability. Few effective therapies improve walking performance in people with PAD. Metformin is a widely available and inexpensive therapy for type 2 diabetes with pleiotropic effects that include activating AMP-activated protein kinase, reducing oxidative stress, and stimulating endothelial nitric oxide synthase (eNOS).

Objective

To determine whether metformin improves 6-minute walk distance, compared with placebo, in people with PAD and without diabetes at 6-month follow-up. Design, Setting, and Participants Randomized double-blind clinical trial involving 4 centers in the US. Enrollment began May 23, 2017, and ended on February 17, 2025, with 202 of the targeted 212 (95%) enrolled, due to funding limitations. Participants were adults aged 50 years and older with PAD. Final follow-up occurred August 19, 2025.

Interventions

Participants with PAD were randomized to receive either metformin (n = 97) or placebo (n = 105) for 6 months. Main Outcomes and Measures The primary outcome was 6-month change in 6-minute walk distance (minimum clinically important difference, 8 to 20 m). Secondary outcomes were maximal treadmill walking time, pain-free treadmill walking time, the Walking Impairment Questionnaire distance and speed scores, the Short-Form 36 physical functioning score, and brachial artery flow-mediated dilation. Results were adjusted for site and the baseline value for each outcome measure.

Results

Of 202 randomized patients (mean [SD] age, 69.6 [8.4] years, 56 [28%] female, 79 [39%] Black), 179 (89%) completed 6-month follow-up. Metformin did not significantly improve 6-minute walk distance compared with placebo (metformin: 358.6 to 353.2 m, within-group change: −5.4 m; placebo: 359.8 to 354.5 m, within-group change: −5.3 m, adjusted between-group difference: 1.1 m [95% CI, −16.3 to 18.6 m]; P = .90). Compared with placebo, metformin did not significantly improve any secondary outcomes. The most common serious adverse events were cardiovascular events (3.1% for metformin and 1.9% for placebo). The most common nonserious adverse events were indigestion/stomach upset (64.9% for metformin and 40.6% for placebo) and headache (37.2% for metformin and 49.5% for placebo). Conclusions and Relevance Among people with PAD without diabetes, metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support metformin for improving walking performance in patients with PAD. Trial Registration ClinicalTrials.gov Identifier: NCT03054519

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsLower ExtremityMetforminPeripheral Arterial DiseaseWalkingAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodWalk TestTreatment OutcomeHeadacheDyspepsiaAnkle Brachial Index

Substanzen

Hypoglycemic AgentsMetformin

Autor:innen und Institutionen

  • Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Department of Statistics, Stanford University, Palo Alto, California.
  • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Department of Epidemiology, Tulane University, New Orleans, Louisiana.
  • Department of Surgery, University of Florida, Gainesville.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

McDermott, M. M., Domanchuk, K. J., Tian, L., Zhao, L., Zhang, D., Bazzano, L., Berceli, S., Criqui, M. H., Ferrucci, L., Guralnik, J. M., Leeuwenburgh, C., Ho, K. J., Ismaeel, A., Kibbe, M. R., Korcarz, C., Kosmac, K., Lloyd-Jones, D., Peterson, C. A., Stein, J. H., …, & Polonsky, T. S. (2026). Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease. JAMA, 335(5), 407. https://doi.org/10.1001/jama.2025.21358

Vancouver

McDermott MM, Domanchuk KJ, Tian L, Zhao L, Zhang D, Bazzano L, et al. Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease. JAMA. 2026;335(5):407. doi:10.1001/jama.2025.21358

BibTeX
@article{McDermott2026,
  author = {McDermott, Mary M and Domanchuk, Kathryn J and Tian, Lu and Zhao, Lihui and Zhang, Dongxue and Bazzano, Lydia and Berceli, Scott and Criqui, Michael H and Ferrucci, Luigi and Guralnik, Jack M and Leeuwenburgh, Christiaan and Ho, Karen J and Ismaeel, Ahmed and Kibbe, Melina R and Korcarz, Claudia and Kosmac, Kate and Lloyd-Jones, Donald and Peterson, Charlotte A and Stein, James H and Sufit, Robert and Wilkins, John and Polonsky, Tamar S},
  title = {Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {5},
  pages = {407},
  doi = {10.1001/jama.2025.21358}
}
Kostenlos starten →